Our top pick for
Building a portfolio
Aptorum Group Limited is a biotechnology business based in the US. Aptorum Group shares (APM) are listed on the NASDAQ and all prices are listed in US Dollars. Aptorum Group employs 36 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$1.16 - $4.98|
|50-day moving average||$3.34|
|200-day moving average||$2.65|
|Wall St. target price||$13.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.65|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$-259,379|
|Return on assets TTM||-47.55%|
|Return on equity TTM||-84.08%|
|Market capitalisation||$109.2 million|
TTM: trailing 12 months
There are currently 334,111 Aptorum Group shares held short by investors – that's known as Aptorum Group's "short interest". This figure is 31.6% up from 253,830 last month.
There are a few different ways that this level of interest in shorting Aptorum Group shares can be evaluated.
Aptorum Group's "short interest ratio" (SIR) is the quantity of Aptorum Group shares currently shorted divided by the average quantity of Aptorum Group shares traded daily (recently around 522048.4375). Aptorum Group's SIR currently stands at 0.64. In other words for every 100,000 Aptorum Group shares traded daily on the market, roughly 640 shares are currently held short.
However Aptorum Group's short interest can also be evaluated against the total number of Aptorum Group shares, or, against the total number of tradable Aptorum Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aptorum Group's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Aptorum Group shares in existence, roughly 10 shares are currently held short) or 0.04% of the tradable shares (for every 100,000 tradable Aptorum Group shares, roughly 40 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aptorum Group.
Find out more about how you can short Aptorum Group stock.
We're not expecting Aptorum Group to pay a dividend over the next 12 months.
Aptorum Group's shares were split on a 3:1 basis on 1 May 2011. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Aptorum Group shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Aptorum Group shares which in turn could have impacted Aptorum Group's share price.
Over the last 12 months, Aptorum Group's shares have ranged in value from as little as $1.16 up to $4.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptorum Group's is -0.1609. This would suggest that Aptorum Group's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aptorum Group has bucked the trend.
Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. .
Everything we know about the Talaris Therapeutics IPO, plus information on how to buy in.
Everything we know about the Sagimet Biosciences IPO, plus information on how to buy in.
Everything we know about the Zenvia IPO, plus information on how to buy in.
Everything we know about the Grove IPO, plus information on how to buy in.
Everything we know about the Pasithea Therapeutics IPO, plus information on how to buy in.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.